Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years

scientific article published on September 2011

Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.4161/HV.7.9.15999
P8608Fatcat IDrelease_bgoaaa7obbaahie5fcms5fwfjm
P932PMC publication ID3225769
P698PubMed publication ID21892005
P5875ResearchGate publication ID51618391

P50authorJacek WysockiQ11715678
Marek SpaczyńskiQ107396894
P2093author name stringAchim Schneider
Tino F Schwarz
Dominique Descamps
Gregory Catteau
Florence Thomas
Andrzej Galaj
Karin Schulze
Sylviane M Poncelet
P2860cites workImmunosenescence and influenza vaccine efficacyQ37600681
Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.Q40227526
Monophosphoryl lipid A as an adjuvant. Past experiences and new directionsQ40408110
Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon natureQ43446049
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 yearsQ43452461
Persistence of specific antibodies after hepatitis B vaccinationQ43489279
Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responsesQ43782984
Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trialsQ44324590
Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvantQ45403548
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialQ45552005
HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectivesQ45734349
Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentrationQ45759554
Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccQ51865830
Maintenance of serological memory by polyclonal activation of human memory B cells.Q52008907
Humoral immunity due to long-lived plasma cells.Q52040025
The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis.Q52945818
Human papillomavirus and cervical cancerQ54023273
Are booster immunisations needed for lifelong hepatitis B immunity?Q54226776
Hepatitis B vaccination: how long does protection last?Q72586604
Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B ImmunityQ73465852
Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 yearsQ82674941
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trialQ83988269
Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult womenQ84579133
The causal relation between human papillomavirus and cervical cancerQ24673148
Global cancer statistics, 2002Q27860562
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trialQ28236008
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenQ28251260
Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 yearsQ28255234
Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, CervarixQ28268292
Prevalence of HPV infection among females in the United StatesQ28290509
Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasiaQ28296557
Epidemiologic classification of human papillomavirus types associated with cervical cancerQ29616213
Human papillomavirus is a necessary cause of invasive cervical cancer worldwideQ29617514
Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.Q30730983
Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infectionQ33698774
Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomasQ33707499
In Vivo Mechanisms of Vaccine-Induced Protection against HPV InfectionQ34125906
A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa RicaQ34557325
Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt onlyQ34568949
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trialQ34580726
Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysisQ34642665
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectivesQ34655188
Hepatitis B vaccine -- do we need boosters?Q35056955
Antigen dependent and independent mechanisms that sustain serum antibody levelsQ35134698
Hepatitis A booster vaccination: is there a need?Q35548831
Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus.Q35854601
Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screeningQ36459799
Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.Q36584350
Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysisQ36670753
Vaccination in the elderly: an immunological perspectiveQ37084886
Age-related decline in immunity: implications for vaccine responsivenessQ37150322
Immunobiology of HPV and HPV vaccinesQ37161653
P433issue9
P921main subjectcervix uterine cancerQ160105
P304page(s)958-965
P577publication date2011-09-01
P1433published inHum VaccinQ15755183
P1476titlePersistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years
P478volume7

Reverse relations

cites work (P2860)
Q41378317Acceptability of human papillomavirus vaccines among women older than 26 years
Q34102466Alternative dosage schedules with HPV virus-like particle vaccines
Q92867229An investigation into the role of chronic Schistosoma mansoni infection on Human Papillomavirus (HPV) vaccine induced protective responses
Q37709718Does the HPV vaccination programme have implications for cervical screening programmes in the UK?
Q36977720Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study
Q34291136Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years.
Q36978399Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule
Q28081156Long-term efficacy and safety of human papillomavirus vaccination
Q35550810Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females
Q35810353Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study
Q30780649Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme
Q38735932Predictors of Adults' Knowledge and Awareness of HPV, HPV-Associated Cancers, and the HPV Vaccine: Implications for Health Education
Q38460201Present status of human papillomavirus vaccine development and implementation
Q26749285Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology Guideline
Q54217505Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Q33162724Safety of human papillomavirus vaccines: a review.
Q36978409Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination
Q34733896Vulval cancer and HPV vaccination in recurrent disease

Search more.